Clinical trials: Vaginal Yeast Infections
Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth
Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa
This cohort study plans to investigate associations between the presence of multiple lower genital tract microorganisms in pregnancy and gestational age at birth.
- Conditions
- Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth, Pregnancy; Infection, Microbial Colonization
- Trial name
- NCT06131749
- Testing
- No intervention
- Where
- South Africa
- Volunteers
- 603 people
- Sponsor
- University of Bern
Vaginal Infection, ASC-US
Probiotic Implementation as Help in Solving Vaginal Infections
Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women's well-being.
- Trial name
- NCT03372395
- Testing
- Lactobacillus rhamnosus BMX 54
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Bacterial Vaginosis, Candida Albicans Vulvovaginitis
Evaluation of a Rapid Microscopic Diagnostic System for Different Vaginitis Conditions
Evaluate the diagnostic performance of the Gyni™ device to detect different vaginitis conditions by comparison to microscopic diagnosis and related lab tests.
- Conditions
- Bacterial Vaginosis, Candida Albicans Vulvovaginitis, Candida Vulvovaginitis, Trichomonas Vaginitis
- Trial name
- NCT04219605
- Where
- Israel
- Volunteers
- 226 people
- Sponsor
- Meir Medical Center
Microbiome, Antibiotic-Induced VVC
Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women
Background: Vaginal yeast infections are caused by a fungus called Candida. Candida can live harmlessly in the vagina, but most women will have symptoms from a vaginal yeast infection at some point during their life.
- Conditions
- Microbiome, Antibiotic-Induced VVC, Vaginal Candidiasis
- Trial name
- NCT01915251
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Vaginosis
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
A Phase II randomized, double-blind, placebo-controlled study screening approximately 600 adult females, aged 18-55, with a goal to enroll approximately 250 participants to achieve 200 evaluable participants at the test of cure…
- Trial name
- NCT03930745
- Testing
- TOL-463
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vulvovaginal Candidiasis
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
This is a multi-centre, multi-national study to evaluate the clinical performance and safety of treatment with Gedea Pessary in adult women with confirmed vulvovaginal candidiasis (VVC).
- Trial name
- EpHect (NCT05507333)
- Testing
- pHyph generation II
- Where
- 4 sites in Sweden
- Volunteers
- 26 people
- Sponsor
- Gedea Biotech AB
Vaginitis, Bacterial Vaginosis
Point of Care Diagnosis of Vaginal Infections
Vaginal infections are a common gynecologic issue and may cause significant symptoms and discomfort for individuals. Point of care tests are used to diagnose infections in the office, with an advantage of quick diagnosis and…
- Conditions
- Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
- Trial name
- PAT (NCT06438575)
- Testing
- Xpert® Xpress MVP test, Usual Care
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Sharon L Hillier
Vulvovaginal Candidiasis, Vaginal Yeast Infections
Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common.
- Trial name
- NCT05895162
- Testing
- JUVIA zinc containing vaginal gel treatment, Fluconazole 150Mg Tab
- Where
- Hungary
- Volunteers
- 64 people
- Sponsor
- FEMPHARMA Kft.
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
The objective of this study is to determine clinical cure rate and safety of a proprietary Vaginal Cooling Device (VCD) in women with VCC.
- Trial name
- NCT06983041
- Testing
- vaginal cooling device
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Coologics, Inc
Candidiasis, Vulvovaginal, Candidiasis of Vagina
Non-ablative Er:YAG for Recurrent Candidiasis
The objective of the study wa to assess the safety, acceptability and effectiveness of non-ablative Er:YAG laser therapy for treatment of symptoms and microbiological conditions of women with recurrent vulvovaginal candidiasis…
- Conditions
- Candidiasis, Vulvovaginal, Candidiasis of Vagina, Candidiasis, Genital, Recurrent Candidiasis of Vagina
- Trial name
- NCT06572488
- Testing
- Non-ablative SMOOTH mode Er:YAG laser
- Where
- Argentina
- Volunteers
- 167 people
- Sponsor
- Espacio Gaspar Clinic
Candidiasis, Vulvovaginal
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
The purpose of this study is to determine if the novel oral agent VT-1161 is safe and effective in treating patients with acute vulvovaginal candidiasis (also referred to as yeast infection).
- Trial name
- NCT01891331
- Testing
- VT-1161, Fluconazole
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Viamet
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd
Candidiasis, Vulvovaginal
Vulvovaginal Candidiasis in Canadian Females
Vulvovaginal candidiasis (VVC; colloquially referred to as a 'yeast infection') is a prevalent mucosal infection caused by Candida spp. that affects ~75% of women at least once in their life.
- Trial name
- THRIVE-yeast (NCT04930107)
- Testing
- Fluconazole 150 mg, Boric Acid Supp,Vag
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Bacterial Vaginosis, Vulvovaginal Candidiasis
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront…
- Trial name
- ELINA (NCT06450990)
- Testing
- BGY-1601-VT
- Volunteers
- 165 people
- Sponsor
- NEXBIOME THERAPEUTICS
Vulvovaginal Candidiasis, Candida Infection
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply…
- Conditions
- Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Trial name
- NCT06954493
- Testing
- Ibrexafungerp
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
- Trial name
- NCT05399641
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- Scynexis, Inc.
Bacterial Vaginosis, Yeast Infection
A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.
This virtual randomized controlled trial evaluates the efficacy of a prebiotic and probiotic supplement in providing relief from symptoms associated with bacterial vaginosis and yeast infections.
- Trial name
- NCT06665126
- Testing
- Prebiotic + Probiotic Supplement
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Happy V
Candidiasis, Vulvovaginal
Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis
This study evaluated the effect of a vaginal gel containing three live probiotic bacteria on vaginal Candida albicans infection in flemish patients (n=20).
- Trial name
- NCT03975569
- Testing
- Probiotic vaginal gel
- Volunteers
- 20 people
- Sponsor
- University Hospital, Antwerp
Vulvovaginal Candidiases, Yeast Infection
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal
- Trial name
- NCT03167957
- Testing
- Oral Encochleated Amphotericin B (CAMB)
- Where
- United States
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03561701)
- Testing
- Oteseconazole (VT-1161)
- Where
- 14 sites in United States
- Volunteers
- 425 people
- Sponsor
- Mycovia Pharmaceuticals Inc.